The Latest

  • COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Board of Directors
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
  • Our Clinical Trials
    • CNP-106 Myasthenia Gravis
  • Publications & Media
    • Press Releases
    • Publications
  • Careers

This video has been provided for informational purposes about COUR’s nanoparticle (CNP) technology. The CNP platform products are investigational and have not yet been approved by the FDA or any other regulatory body.

Our Technology

COUR’s breakthrough nanoparticle platform harnesses the immune system’s own learning power to induce tolerance to specific problematic antigens, while preserving all immune functionality.

Upon infusion, COUR nanoparticles bind to immune cells called monocytes. The particles surface is functionalized to enhance uptake, ensuring optimal targeted delivery.

These cells then travel to the spleen and liver, where they undergo apoptosis. There, the disease-specific antigens encapsulated within the particles are released.

The resulting debris is consumed by antigen presenting cells, which present the disease-specific antigens along with negative co-stimulating factors to the adaptive immune system. Adaptive immune T-cells interact with the antigen-presenting cells, and in the absence of inflammatory signals they “perceive” the antigen as self.

These T-cells respond by undergoing deletion or anergy… or by inducing a T regulatory response.

T regulatory cells then migrate to sites of disease, where they continually down regulate the immune response in the presence of the disease specific antigen.

By harnessing the immune system’s built-in learning and regulatory pathways, COUR nanoparticle technology can reprogram the immune system – providing clinicians with a breakthrough approach to treating autoimmune disease.

In Our Pipeline

We are rapidly advancing first-in-class therapies based on our proprietary antigen-specific immune tolerance platform, designed to reprogram the immune system to address the underlying root causes of immune-mediated diseases. Data from multiple clinical and preclinical programs have demonstrated the ability of COUR’s product candidates to induce antigen-specific immune tolerance, offering the potential to treat a wide range of autoimmune diseases.

View COUR’s Pipeline
In Our Pipeline

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2025

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top